Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
Recruiting
Phase 4
Interventional Study
Anticoagulation
Coronary Endarterectomy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 202 (estimated)
- Sponsor
- China National Center for Cardiovascular Diseases · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult patients with diffuse coronary artery disease undergoing CE+CABG during the study period.
* No contraindications for both dual antiplatelet therapy and anticoagulation therapy with warfarin.
* Must be able to swallow tablets after the surgery.
Exclusion Criteria:
1. Pa…
Contacts